NCT03723772View on ClinicalTrials.gov

A Research Study of How Different Doses of a New Medicine NNC0148-0287 C (Insulin 287) Work on the Blood Sugar in People With Type 1 Diabetes When it is Taken Once a Week

PHASE1CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

November 29, 2018

Primary Completion Date

June 26, 2020

Study Completion Date

June 26, 2020

Conditions
Diabetes Mellitus, Type 1
Interventions
DRUG

Insulin icodec

Participants will receive subcutaneous injections of insulin 287 once weekly for 8 weeks

DRUG

IGlar U100

Participants will receive subcutaneous injections of insulin glargine once weekly for 2 weeks.

Trial Locations (1)

41460

Profil Institut für Stoffwechselforschung GmbH, Neuss

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY